



**June 09, 2026**

To,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai 400001

**Scrip code: 543916**

**Sub.: Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Press Release**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Press Release being issued by the Company titled "**Hemant Surgical Strengthens Healthcare Portfolio Through Strategic Acquisition of Majority Stake in Lifesenz Cancer Research Labs**".

Request you to take the same on record.

Thanking you,

Yours faithfully,  
**For Hemant Surgical Industries Limited**

**Hanskumar Shamji Shah**  
**Managing Director**  
**DIN: 00215972**  
**Email id: [hanskumar@hemantsurgical.com](mailto:hanskumar@hemantsurgical.com)**

**Press Release**

**Hemant Surgical Strengthens Healthcare Portfolio Through Strategic Acquisition of Majority Stake in Lifesenz Cancer Research Labs**

**Mumbai (June 09, 2026):** Hemant Surgical Industries Limited [BSE Scrip Code: 543916] ("**Hemant Surgical**" or "**the Company**"), an internationally acclaimed manufacturer of medical disposable, surgical equipment, pharmaceutical products, and exporter/Importer as well as a marketer in India and around the world, has completed the strategic acquisition of a majority stake (66.66%) in Lifesenz Cancer Research Labs Private Limited ("**Lifesenz**"), a company focused on precision oncology and personalized cancer treatment solutions for an amount of Rs. 19.98 Crores, making **Lifesenz** a subsidiary of the Company with effect from June 01, 2026.

**Expanding into a High-Growth Segment of Healthcare**

Globally oncology remains one of the fastest-growing healthcare segments, driven by increasing cancer incidence, growing demand for personalized treatment approaches, and continued innovation in cancer care. **Lifesenz** operates in the field of precision oncology by assisting clinicians with patient-specific treatment selection through advanced ex-vivo chemo-sensitivity analysis using patient-derived 3D cancer cell models. This approach enables oncologists to evaluate the likely effectiveness of different treatment options on a patient's own cancer cells before therapy is administered, supporting more informed clinical decision-making.

The acquisition represents an important step in the Company's long-term strategy to expand beyond traditional healthcare distribution and participate in emerging areas of advanced diagnostics and precision medicine.

**Building on Existing Strengths**

**Hemant Surgical** has built a strong presence in the healthcare sector through its established distribution capabilities, customer relationships, institutional engagement, and market reach. The integration of **Lifesenz's** scientific and oncology-focused capabilities with the Company's healthcare ecosystem is expected to create opportunities to:

- ✓ expand the Company's participation in specialized healthcare and oncology markets.
- ✓ strengthen relationships with hospitals, clinicians, and healthcare institutions.
- ✓ enhance the Company's portfolio with differentiated healthcare solutions.
- ✓ increase exposure to innovation-led segments with long-term growth potential.
- ✓ create a platform for future expansion in precision medicine and advanced cancer care services.

The Company believes the acquisition creates a compelling strategic fit with its existing healthcare platform.

502,5<sup>th</sup> Floor, Estacy, JSD Road, City of Joy Commercial, Mulund (W), Mumbai-400 080.

Tel. : +91-22-2591 2747

Email: [info@hemantsurgical.com](mailto:info@hemantsurgical.com), [sales@hemantsurgical.com](mailto:sales@hemantsurgical.com), Web : [www.hemantsurgical.com](http://www.hemantsurgical.com)

CIN: L33110MH1989PLC051133

## Established Industry Collaborations

As awareness of personalized cancer treatment continues to grow, management believes the demand for technologies that improve treatment selection and clinical outcomes is likely to increase over the coming years.

**Lifesenz** has developed collaborations with hospitals, oncologists, research institutions, and other healthcare stakeholders. The Company believes these relationships provide a foundation for scaling operations and expanding adoption of precision oncology solutions in India.

## Long-Term Value Creation Approach

The Company acknowledges that **Lifesenz** is currently in a growth and development phase, reflecting investments in research, technology, infrastructure, and market expansion and will take some time to break even and eventually add financial synergies to the Company. The acquisition has, therefore, been evaluated through a long-term strategic and objective lens by the Board of Directors of the Company and taking into account the strategic advantages that accrue to the Company immediately rather than near-term profitability metrics. The acquisition has been completed purely on arm's length basis, considering the best interest of the Company.

The Company intends to take following initiatives to enable **Lifesenz** to contribute meaningfully to future revenue growth and long-term shareholder value creation as the business matures:

- ✓ Scaling operational capabilities.
- ✓ Strengthening clinical and institutional collaborations.
- ✓ Expanding patient adoption.
- ✓ Increasing commercialization opportunities.
- ✓ Supporting innovation in precision oncology.

## Management Commentary

Commenting on the acquisition, Mr. Hanskumar Shamji Shah, Managing Director of Hemant Surgical Industries Limited stated:

*"Precision oncology is an area of significant clinical importance and growing global relevance. The acquisition of Lifesenz reflects our commitment to participate in the future of healthcare. **By combining Lifesenz's scientific expertise with Hemant Surgical's established healthcare platform, we are creating a foundation for long-term growth while contributing to improved patient care outcomes.** We believe this investment positions the Company to participate in a transformative segment of healthcare and create sustainable value for our stakeholders."*

**About Hemant Surgical Industries Limited**

**Hemant Surgical Industries Limited** is a BSE SME Listed, CDSCO compliant Company established in 1985 in Mumbai dedicated to importing, manufacturing, and marketing premium quality surgical and pharmaceutical products at economical prices, making advanced healthcare accessible across India. The Company continues to focus on expanding its healthcare presence, pursuing growth opportunities, and creating long-term value for shareholders through strategic initiatives and operational excellence.

**Forward-Looking Statement**

This press release contains forward-looking statements regarding future business prospects, expected synergies, growth opportunities, and market developments. Actual results may differ materially due to market conditions, regulatory developments, execution risks, and other factors beyond the Company's control.

**For further details please contact:**

502, 5<sup>th</sup> Floor, Ecstasy Business Park, Near City of Joy,  
JSD Road, Mulund West, Mumbai, Maharashtra – 400080;  
+91-22-2591 2747  
[cs@hemantsurgical.com](mailto:cs@hemantsurgical.com) / [info@hemantsurgical.com](mailto:info@hemantsurgical.com)